

Ref. No: 005010422  
From: Commercial  
Date: 01/04/22  
Subject: Jakavi

## REQUEST & RESPONSE

The purpose of these questions is to understand the variability of treatment within your trust and in context to the rest of the country.

**Q1. Does your trust treat myelofibrosis? If not, which other trust do you refer these patients to?**

The Pharmacy system does not record the indication an item is prescribed for, so we do not have this information.

**Q2.**

**A) Please provide the total number of patients treated in the last 6 months (or the latest 6 months data you have available) for myelofibrosis (ICD10 code D47.4).**

7 patients were diagnosed in the last 6 months (Oct 2021 to Mar 2022) with myelofibrosis.

**b) How many of these patients were above age 65?**

All 7 patients were above the age of 65.

**Q3. How many myelofibrosis patients were treated in the past 6 months with Ruxolitinib?**

The Pharmacy system does not record the indication an item is prescribed for, so we do not have this information.

**Q4.**

**a) How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?**

There have been 77 patients diagnosed in the past 3 years with myelofibrosis.

**b) Of these patients, how many were treated in the past 6 months (or the latest 6 months data you have available) with:**

- **Hydroxyurea**
- **Fedratinib**
- **Received No Treatment**

The Pharmacy system does not record the indication an item is prescribed for, so we do not have this information.

**Q5. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.**

There are no current trials for ITP.